Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcutis Biotherapeutics (ARQT) Accounts Payables: 2020-2025

Historic Accounts Payables for Arcutis Biotherapeutics (ARQT) over the last 6 years, with Sep 2025 value amounting to $5.8 million.

  • Arcutis Biotherapeutics' Accounts Payables fell 70.01% to $5.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.8 million, marking a year-over-year decrease of 70.01%. This contributed to the annual value of $14.2 million for FY2024, which is 18.58% up from last year.
  • Arcutis Biotherapeutics' Accounts Payables amounted to $5.8 million in Q3 2025, which was down 61.58% from $15.1 million recorded in Q2 2025.
  • Arcutis Biotherapeutics' Accounts Payables' 5-year high stood at $24.5 million during Q1 2025, with a 5-year trough of $2.7 million in Q2 2021.
  • Moreover, its 3-year median value for Accounts Payables was $13.2 million (2023), whereas its average is $14.1 million.
  • In the last 5 years, Arcutis Biotherapeutics' Accounts Payables spiked by 296.25% in 2022 and then crashed by 70.01% in 2025.
  • Quarterly analysis of 5 years shows Arcutis Biotherapeutics' Accounts Payables stood at $7.4 million in 2021, then grew by 20.05% to $8.8 million in 2022, then spiked by 35.86% to $12.0 million in 2023, then grew by 18.58% to $14.2 million in 2024, then plummeted by 70.01% to $5.8 million in 2025.
  • Its Accounts Payables stands at $5.8 million for Q3 2025, versus $15.1 million for Q2 2025 and $24.5 million for Q1 2025.